Prosecution Insights
Last updated: November 04, 2026

Hebei Grandios Pharma Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Hebei Grandios Pharma Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is assigned to AULAKH, CHARANJIT, who is the 1 examiner and the busiest examiner for the company with 1 pending file. The prosecution is localized in 1 distinct art unit, reflecting a focused technical review. For a patent practitioner, the concentration of 1 pending office action under 1 examiner means that the immediate prosecution strategy is singular.

There is no need to coordinate across different art units or examiner styles at this time. The workload is minimal, with AULAKH, CHARANJIT handling the entirety of the company's pending USPTO matters. Practitioners should prioritize direct communication with AULAKH, CHARANJIT to resolve the 1 pending office action efficiently. This streamlined profile suggests a very specific interaction with the patent office in the Biotechnology & Pharmaceuticals sector. The lack of diversity in examiners and art units simplifies the administrative process but places high importance on the outcome of this 1 matter.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
AULAKH, CHARANJIT 1 80.7% -14.5%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18813075 DIBENZODIAZEPINE COMPOUNDS AND USE IN INTERFERON ACTIVATOR PROTEIN AGONISTS THEREOF AULAKH, CHARANJIT —

Top Art Units

Art UnitApps
1621 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18813075 DIBENZODIAZEPINE COMPOUNDS AND USE IN INTERFERON ACTIVATOR PROTEIN AGONISTS THEREOF AULAKH, CHARANJIT 1621 §102§112 Non-Final OA — Pending Aug 23, 2024

Managing Hebei Grandios Pharma Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Hebei Grandios Pharma Co. Ltd. have?

Hebei Grandios Pharma Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Hebei Grandios Pharma Co. Ltd. applications?

Charanjit Aulakh has the most, with 1 of Hebei Grandios Pharma Co. Ltd.'s pending office actions.

What technology area are Hebei Grandios Pharma Co. Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month